Bladder cancer is the one of the most common cancers worldwide and O6-Methylguanine DNA Methyltransferase (MGMT) promoter methylation might be contributing to clinicopathological features of the disease. We analyzed formalin-fixed, paraffin-embedded bladder tissue samples from 101 patients with urothelial carcinoma. All samples were analyzed by real-time methylation-specific PCR. MGMT promoter methylation was detected in 15 (14.9%) of the samples and was not significantly different between any of the groups, although the number of high grade tumors with MGMT promoter methylation was twice the number of low grade tumors. Methylation of MGMT in high grade tumors might play a role in aggressive proliferation of the tumor cells and a poor prognosis.